William Blair analyst Myles Minter downgraded Alector (ALEC) to Market Perform from Outperform without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm needs to see clinical data for Alector’s platform to evaluate its other programs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector downgraded to Neutral from Overweight at Cantor Fitzgerald
- Alector downgraded to Neutral from Outperform at Mizuho
- Alector downgraded to Hold from Buy at TD Cowen
- Closing Bell Movers: Intuitive Surgical, Capital One jump after earnings
- Alector discontinues extension portion of INFRONT-3 trial